(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday - 2Vote In favor of Your #1 Method for lessening Pressure
- 36 Well known Nissan Vehicles in the U.S.
- 435 million tons of food go to waste yearly in the US. Experts share tips to help stop it
- 5Vote in favor of your Number one Kind of Gems
- The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
- 6 Robot Vacuum Cleaners for Easy Home Cleaning
- The most effective method to Amplify Profits from Gold Speculation: Systems and Tips
- Pick Your Number one breakfast food
- How comfort foods trigger pleasure in our brains
- A few Exemplary Chinese Dishes, Which Are Famous Around the world
- Pick Your #1 Kind Of Treat
- Independence from the rat race: How to Save and Contribute Shrewdly
- 5 Must-Attempt Outlandish Dishes from Around the World
